Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:420844rdf:typepubmed:Citationlld:pubmed
pubmed-article:420844lifeskim:mentionsumls-concept:C0006675lld:lifeskim
pubmed-article:420844lifeskim:mentionsumls-concept:C0026844lld:lifeskim
pubmed-article:420844lifeskim:mentionsumls-concept:C0041175lld:lifeskim
pubmed-article:420844lifeskim:mentionsumls-concept:C0243144lld:lifeskim
pubmed-article:420844pubmed:issue2lld:pubmed
pubmed-article:420844pubmed:dateCreated1979-5-26lld:pubmed
pubmed-article:420844pubmed:abstractTextThis report demonstrates that the commonly used buffering agent Tris(hydroxymethyl)aminomethane (Tris) in concentrations of 5 and 30 mM inhibits calcium (Ca2+) uptake in both rat aortic and portal venous smooth muscle. The data indicates that total exchangeable Ca2+ in portal vein is reduced by about 35% in 5 or 30 mM Tris, while the intracellular exchangeable Ca2+ is not significantly altered. On the other hand, in aortic smooth muscle, while 30 mM Tris reduces total exchangeable Ca2+ by about 20%, intracellular Ca2+ is reduced by 44% in 5 mM Tris and by 55% in 30 mM Tris. The present studies, thus, reveal that Tris exerts significant inhibitory effects on exchangeability and transmembrane movement of Ca2+ in at least two different types of smooth muscle.lld:pubmed
pubmed-article:420844pubmed:languageenglld:pubmed
pubmed-article:420844pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:420844pubmed:citationSubsetIMlld:pubmed
pubmed-article:420844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:420844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:420844pubmed:statusMEDLINElld:pubmed
pubmed-article:420844pubmed:monthMarlld:pubmed
pubmed-article:420844pubmed:issn0006-3002lld:pubmed
pubmed-article:420844pubmed:authorpubmed-author:AlturaB MBMlld:pubmed
pubmed-article:420844pubmed:authorpubmed-author:AlturaB TBTlld:pubmed
pubmed-article:420844pubmed:authorpubmed-author:TurlapatyP...lld:pubmed
pubmed-article:420844pubmed:issnTypePrintlld:pubmed
pubmed-article:420844pubmed:day8lld:pubmed
pubmed-article:420844pubmed:volume551lld:pubmed
pubmed-article:420844pubmed:ownerNLMlld:pubmed
pubmed-article:420844pubmed:authorsCompleteYlld:pubmed
pubmed-article:420844pubmed:pagination459-62lld:pubmed
pubmed-article:420844pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:420844pubmed:meshHeadingpubmed-meshheading:420844-A...lld:pubmed
pubmed-article:420844pubmed:meshHeadingpubmed-meshheading:420844-C...lld:pubmed
pubmed-article:420844pubmed:meshHeadingpubmed-meshheading:420844-R...lld:pubmed
pubmed-article:420844pubmed:meshHeadingpubmed-meshheading:420844-A...lld:pubmed
pubmed-article:420844pubmed:meshHeadingpubmed-meshheading:420844-P...lld:pubmed
pubmed-article:420844pubmed:meshHeadingpubmed-meshheading:420844-M...lld:pubmed
pubmed-article:420844pubmed:meshHeadingpubmed-meshheading:420844-M...lld:pubmed
pubmed-article:420844pubmed:meshHeadingpubmed-meshheading:420844-B...lld:pubmed
pubmed-article:420844pubmed:meshHeadingpubmed-meshheading:420844-T...lld:pubmed
pubmed-article:420844pubmed:meshHeadingpubmed-meshheading:420844-O...lld:pubmed
pubmed-article:420844pubmed:year1979lld:pubmed
pubmed-article:420844pubmed:articleTitleTris(hydroxymethyl)aminomethane inhibits calcium uptake in vascular smooth muscle.lld:pubmed
pubmed-article:420844pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:420844pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:420844pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:420844lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:420844lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:420844lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:420844lld:pubmed